Key facts
- Korio’s last known valuation is $17.0M.
- It has raised $12.3M; the latest was Early Stage VC ($5.5M) in Aug 2024.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, First Trust Capital Partners, BIP Ventures, Boston Millennia Partners, Excelerate Health Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Korio
- ·The full record, as it builds
Funding rounds
No funding rounds for Korio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Korio
Developer of a compliance-centric platform designed for randomisation and trial supply management. The company's role-based interface features randomisation, trial supply management and data management functionalities and also gives direct access to the leadership team, enabling users to work efficiently and with confidence.
- Sector
- Healthcare
- HQ
- Doylestown, PA, United States
- Founded
- 2021
- Employees
- 30
- Website
- korioclinical.com/
- Ownership
- Privately Held (backing)
Korio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Korio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Korio in its N-PORT filings yet. We sweep new filings monthly.